These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 32966167)

  • 1. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
    Jiang L; Li R; Yan F; Yap TA; Yuan Y
    Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies.
    Tian F; Lin R; Wang L; Yuan Y
    Stat Methods Med Res; 2024 Jun; 33(6):931-944. PubMed ID: 38573788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A generalized Bayesian optimal interval design for dose optimization in immunotherapy.
    Xia Q; Takeda K; Yamaguchi Y; Zhang J
    Pharm Stat; 2024; 23(4):480-494. PubMed ID: 38295856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study.
    Yamaguchi Y; Takeda K; Yoshida S; Maruo K
    J Biopharm Stat; 2024 May; 34(3):379-393. PubMed ID: 37114985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
    Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
    Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
    Zang Y; Guo B; Qiu Y; Liu H; Opyrchal M; Lu X
    Clin Trials; 2024 Jun; 21(3):298-307. PubMed ID: 38205644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of adaptive trial designs for dose optimization.
    Zhang J; Chen X; Li B; Yan F
    Pharm Stat; 2023; 22(5):797-814. PubMed ID: 37156731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials.
    Zhou Y; Lin R; Kuo YW; Lee JJ; Yuan Y
    JCO Clin Cancer Inform; 2021 Jan; 5():91-101. PubMed ID: 33439726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian sequential monitoring strategies for trials of digestive cancer therapeutics.
    Mulier G; Lin R; Aparicio T; Biard L
    BMC Med Res Methodol; 2024 Jul; 24(1):154. PubMed ID: 39030498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T3 + 3: 3 + 3 Design With Delayed Outcomes.
    Guo J; Lu M; Wan I; Wang Y; Han L; Zang Y
    Pharm Stat; 2024 Jun; ():. PubMed ID: 38923150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.
    Zhou Y; Li R; Yan F; Lee JJ; Yuan Y
    Stat Biopharm Res; 2021; 13(2):147-155. PubMed ID: 34249223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints.
    Chi X; Yuan Y; Yu Z; Lin R
    Biom J; 2024 Mar; 66(2):e2300122. PubMed ID: 38368277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity.
    Lee J; Thall PF; Ji Y; Müller P
    J Am Stat Assoc; 2015 Jun; 110(510):711-722. PubMed ID: 26366026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A constrained optimum adaptive design for dose finding in early phase clinical trials.
    Alam MI; Bogacka B; Coad DS
    J Biopharm Stat; 2024 Jul; ():1-26. PubMed ID: 38984691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian decision-theoretic design for simultaneous biomarker-based subgroup selection and efficacy evaluation.
    Wang Z; Wang F; Wang C; Zhang J; Wang H; Shi L; Tang Z; Rosner GL
    Stat Biopharm Res; 2022; 14(4):568-579. PubMed ID: 37197312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials.
    Yin J; Yuan Y
    J Biopharm Stat; 2020 Nov; 30(6):1006-1025. PubMed ID: 32966167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.